Preliminary findings from two studies point to low overall rates of breakthrough COVID-19 following vaccination in people with rheumatic and musculoskeletal diseases.
Most people with inflammatory diseases treated with immunomodulatory therapies mount an antibody response to mRNA vaccines against SARS-CoV-2, but the response may be blunted in those taking glucocorticoids or B cell-depleting therapies, shows the COVaRiPAD study.
The American College of Rheumatology has updated its guidance on COVID-19 vaccination for people with rheumatic diseases to include the timing of the third dose of mRNA vaccines in those taking immunomodulatory drugs.
